Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Artios Pharma

Novartis day

Novartis pulls ahead of Merck in MET-positive lung cancer race

FDA starts priority review of Swiss pharma's MET inhibitor

- PMLiVE

Immuno-oncology, personalised medicine continues to drive pharma sector

New GlobalData survey identifies key trends impacting the industry

Bristol Myers Squibb logo

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

A verdict is expected to be delivered by 15 May

- PMLiVE

Lilly ends $1.4bn deal with immuno-oncology biotech NextCure

Lilly paid $25m upfront on top of a $15m equity investment

- PMLiVE

Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Confirmatory trial strengthens claim in therapy area

- PMLiVE

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

Closely follows $3bn acquistion of gene therapy specialist Audentes

- PMLiVE

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Acquisition bolsters immuno-oncology pipeline

- PMLiVE

Merck takes evobrutinib for MS into phase 3, on mixed data

First drug in class to reach this stage for the illness

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

- PMLiVE

AbbVie cures STING fever with Mavupharma acquisition

Joins host of companies pursuing novel mechanism

- PMLiVE

Evotec spins off cancer tech into new Breakpoint company

Will challenge AstraZeneca and others in DNA damage response

- PMLiVE

EMD Serono allies with ‘free sequencing’ firm Nebula

Free genomic sequencing in exchange for data use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links